{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T15:12:17Z","timestamp":1788880337670,"version":"build-2803163510"},"reference-count":14,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Vet Pharm &amp;amp; Therapeutics"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    Clonidine is an \u03b1\u20102 agonist shown to be both well tolerated and useful in the treatment of canine fear\u2010based disorders, although it is perceived to have a short duration of action. Clonidine is available in regular release and extended\u2010release formulations, but canine pharmacokinetic (PK) and pharmacodynamic (PD) data on any clonidine formulation are lacking. The aim of this study was to establish PK and PD parameters of regular release (RR) clonidine in dogs. Clonidine RR (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u20096) was orally administered at 0.05\u2009mg\/kg to laboratory beagles. Clonidine RR showed a maximum concentration (\n                    <jats:italic>C<\/jats:italic>\n                    <jats:sub>max<\/jats:sub>\n                    ) 1.5\u20132\u2009h after administration and declined to below the level of quantification over 4\u20138\u2009h after administration with an elimination half\u2010life (\n                    <jats:italic>T<\/jats:italic>\n                    <jats:sub>1\/2<\/jats:sub>\n                    ) of 0.65\u2009h. Slight reductions in heart rate and increases in sedation scores were seen in all treatment groups. In conclusion, obtained data indicated a single dose of clonidine RR at 0.05\u2009mg\/kg was well tolerated with mild sedation and bradycardia and no other adverse effects in healthy dogs.\n                  <\/jats:p>","DOI":"10.1111\/jvp.70092","type":"journal-article","created":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T05:26:16Z","timestamp":1782278776000},"page":"450-456","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pharmacokinetics of Orally Administered Clonidine in Dogs"],"prefix":"10.1111","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7301-7917","authenticated-orcid":false,"given":"Kevin","family":"Pflaum","sequence":"first","affiliation":[{"name":"Small Animal Clinical Sciences, College of Veterinary Medicine University of Tennessee  Knoxville Tennessee USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3532-3806","authenticated-orcid":false,"given":"Julia","family":"Albright","sequence":"additional","affiliation":[{"name":"Small Animal Clinical Sciences, College of Veterinary Medicine University of Tennessee  Knoxville Tennessee USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5184-900X","authenticated-orcid":false,"given":"Sherry","family":"Cox","sequence":"additional","affiliation":[{"name":"Biomedical and Diagnostic Sciences, College of Veterinary Medicine University of Tennessee  Knoxville Tennessee USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4288-2262","authenticated-orcid":false,"given":"Joe","family":"Smith","sequence":"additional","affiliation":[{"name":"Large Animal Clinical Sciences, College of Veterinary Medicine University of Tennessee  Knoxville Tennessee USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,6,23]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvim.14863"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.2460\/javma.2003.222.744"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.2165\/11208310\u2010000000000\u201000000"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1079\/9781786394552.0000"},{"key":"e_1_2_12_6_1","unstructured":"FDA.2010.\u201cKAPVAY (Clonidine Hydrochloride) Extended\u2010Release Tablets: Highlights of Prescribing Information.\u201d U.S. Food and Drug Administration.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/022331s001s002lbl.pdf."},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jveb.2017.09.008"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.2460\/javma.233.12.1902"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jveb.2012.10.004"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1136\/vr.104045"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12248\u2010021\u201000590\u20100"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jveb.2010.10.004"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1136\/vr.105539"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.2460\/javma.21.03.0167"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1691\/ph.2016.5110"}],"container-title":["Journal of Veterinary Pharmacology and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jvp.70092","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jvp.70092","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jvp.70092","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T14:48:53Z","timestamp":1788878933000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jvp.70092"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,23]]},"references-count":14,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.1111\/jvp.70092"],"URL":"https:\/\/doi.org\/10.1111\/jvp.70092","archive":["Portico"],"relation":{},"ISSN":["0140-7783","1365-2885"],"issn-type":[{"value":"0140-7783","type":"print"},{"value":"1365-2885","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,23]]},"assertion":[{"value":"2026-01-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-23","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}